Project Grant R21AI180263
Award Date
6/18/25
Completion Date
5/31/27
Dollars Obligated
$272K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,453 to Brigham & Women's Hospital Inc. for the development of a rapid, cost-effective point-of-care (POC) hepatitis C virus (HCV) antigen detection test. The research aims to address the global health challenge of HCV infection, which impacts an estimated 58 million individuals worldwide. The project...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel point-of-care nucleic acid amplification test (NAAT) for rapid, pan-genomic diagnosis of hepatitis C virus (HCV) infection. The $3,012,033 award to the University of Washington will fund the creation of a low-complexity, disposable test cartridge capable of extracting and amplifying HCV RNA...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a 5-year, $1,361,442 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to develop an economical, rapid molecular diagnostic system for detecting hepatitis C virus (HCV) and HIV in whole blood samples. The key objectives are to: 1) Adapt and automate RNA sample extraction and stabilization technology to enable HCV/HIV RNA extraction from capillary whole blood, and 2) Apply chemical...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund the development of a novel Janus bead blood assay for point-of-care assessment of hepatitis C virus (HCV) viral load and associated liver damage. The $876,400 award to the University of Notre Dame will integrate microparticle assay and ultrafiltration technologies to create a rapid, one-step diagnostic platform that can...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $537,619 Project Grant (R15AI189259) to the University of Central Florida Board of Trustees Office of Research. The award, with a performance period from March 1, 2025 to February 29, 2028, supports the development of an electrochemical biosensor platform for the simultaneous detection of HIV, hepatitis B, and hepatitis C viruses. The proposed...
The federal Project Grant award of $483,194 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to define the protective CD4+ T cell signature that supports effective CD8+ T cell immunity against hepatitis C virus (HCV) infection. The research will leverage historical blood and liver samples from chimpanzees to characterize HCV-specific CD4+ T cell responses using single-cell...
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The project aims to create a portable, low-cost device that can rapidly diagnose active HCV by detecting viral RNA, eliminating the need for two-step serologic and laboratory-based...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...